Did you predict the major events in the stem cell and regenerative medicine field this year? I tried and today’s post are the grades on my predictions. Prediction is a key part of being a scientist even if we may not think about it that much. For instance, we have to try to predict what […]
Grading my 20 stem cell & regenerative medicine predictions for 2024 Read More »
Intermittent fasting must be good for stem cells, right? It’s not so clear. Like many things in biology, intermittent fasting can have seemingly opposite effects. Before we get into that, the news of the week is that the FDA approved Mesoblast’s Ryoncil MSC drug for some cases of pediatric GvHD. This has sparked lively discussion.
Weekly reads: intermittent fasting and stem cells, vet warning, blastemas Read More »
Toward the end of each year I make predictions for the stem cell and regenerative medicine field for the coming year. I’ve been doing this for more than a dozen years in various forms. In this post I’m looking at the (gene-edited, stemness enriched) tea leaves for 2025 for the regenerative arena. These predictions include
25 stem cell & regenerative medicine predictions for 2025 Read More »
Looking for some stem cell good news? You’ll like today’s post. One mission of this blog The Niche is to promote rigorous science-based regenerative medicine, which can lead to investigating and writing about not-so-upbeat stuff. Risky clinics. People getting hurt. Patient lawsuits. Serious FDA, FTC, or state AG regulatory developments. Such actions can be good
Recent stem cell & regenerative medicine good news Read More »
Each year I make predictions for the stem cell and regenerative medicine field for the following year. Today’s prediction post is focused on what to expect in 2024. You can also see my stem cell predictions for 2023 and my grades on how I did. I also have made a video version of these predictions so please
20 stem cell & regenerative medicine predictions for 2024 Read More »
Every year I make stem cell and regenerative medicine predictions. Looking at my predictions for 2023, they reflect a wild year but in many ways a good one overall. Below I have graded my 2023 predictions. Overall, my crystal ball gave solid results. Some of the predictions have been condensed to keep things concise, but you
2023 stem cell predictions grades reflect wild year for regenerative medicine Read More »
Cell therapy companies face many hurdles. I wrote recently about four cell therapy biotechs that have been really struggling. Blogging here at The Niche for more than a dozen years, I’ve seen many companies even go under. That’s bad news for the field, for patients, and for investors. Today I wanted to highlight some cell therapy
3 cell therapy companies doing well: Vertex, Vericel, & Regeneron Read More »
Paolo Macchiarini is one of a small group of people in the stem cell universe whose misconduct has blown up in the press. Piero Anversa, Haruko Obokata, Hwang Woo-Suk, and some operators in the unproven stem cell clinic sphere come to mind. Macchiarini published quite a few seriously problematic papers, some of which just hung
Weekly reads: late Macchiarini retractions, stem cells & Lululemon Read More »
A days ago the news came about Mesoblast not getting FDA approval for its MSC product for GvHD. The MSC area has had a rough few years with various clinical trials including for COVID. The “stem cells for heart disease” arena has also had a tough time. Here’s more news along these lines: BioCardia pauses enrollment in PhIII trial
Weekly reads: BioCardia, HeLa suit, illegal bio lab in CA Read More »
So many things have gotten very expensive these days that it got me thinking this past week again about stem cell cost. For this reason, I’ve been running polls asking people what they’ve paid for stem cells and how many therapies they’ve gotten. Before jumping into our weekly reads, check out our informational post on
Weekly reads: stem cell cost, trial death, HSCT for MS, Neuralink Read More »